$CLDX
Celldex Therapeutics, Inc.

2014 Q1 Form 10-K Financial Statement

#000104746914001653 Filed on March 03, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013 Q3
Revenue $416.0K $620.0K $980.0K
YoY Change -82.77% -83.0% -68.52%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $980.0K
YoY Change 790.91%
Gross Profit Margin 100.0%
Selling, General & Admin $4.580M $4.680M $3.580M
YoY Change 45.86% 76.6% 26.06%
% of Gross Profit 365.31%
Research & Development $27.07M $17.80M $20.42M
YoY Change 92.12% 29.45% 73.48%
% of Gross Profit 2083.37%
Depreciation & Amortization $579.0K $760.0K $730.0K
YoY Change 23.72% 5.56% -5.19%
% of Gross Profit 74.49%
Operating Expenses $27.07M $22.73M $20.42M
YoY Change 92.12% 36.52% 73.48%
Operating Profit -$31.49M -$23.27M
YoY Change 80.96% 57.75%
Interest Expense $1.590M $50.00K $13.00K
YoY Change 412.9% -119.23% -96.59%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$29.90M -$22.06M -$23.14M
YoY Change 72.53% 31.23% 53.96%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.90M -$22.06M -$23.14M
YoY Change 72.53% 31.23% 53.96%
Net Earnings / Revenue -7187.5% -3558.06% -2361.22%
Basic Earnings Per Share
Diluted Earnings Per Share -$5.025M -$3.982M -$4.285M
COMMON SHARES
Basic Shares Outstanding 89.25M shares 81.11M shares 80.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $274.2M $303.0M $136.6M
YoY Change 50.36% 260.86% 75.98%
Cash & Equivalents $56.90M $169.4M $14.63M
Short-Term Investments $217.3M $133.6M $122.0M
Other Short-Term Assets $2.300M $1.700M $2.500M
YoY Change 15.0% 54.55% 108.33%
Inventory
Prepaid Expenses
Receivables $300.0K $500.0K $900.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $276.8M $305.2M $139.9M
YoY Change 50.08% 258.56% 77.57%
LONG-TERM ASSETS
Property, Plant & Equipment $10.22M $9.973M $8.814M
YoY Change 43.26% 38.42% 16.49%
Goodwill $8.965M $8.965M $8.965M
YoY Change 0.0% 0.0% 0.0%
Intangibles $22.57M $22.82M $23.07M
YoY Change -4.3% -4.25% -4.21%
Long-Term Investments
YoY Change
Other Assets $132.0K $148.0K $157.0K
YoY Change -44.07% -65.09% -61.61%
Total Long-Term Assets $41.88M $41.91M $41.01M
YoY Change 4.93% 3.66% -0.04%
TOTAL ASSETS
Total Short-Term Assets $276.8M $305.2M $139.9M
Total Long-Term Assets $41.88M $41.91M $41.01M
Total Assets $318.7M $347.1M $181.0M
YoY Change 42.04% 176.48% 51.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.414M $2.243M $1.982M
YoY Change 39.29% 201.07% 54.72%
Accrued Expenses $14.97M $17.18M $13.81M
YoY Change 54.42% 56.74% 69.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $19.51M $20.35M $16.80M
YoY Change 6.42% 15.07% 11.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $7.346M $6.950M $7.415M
YoY Change 10.17% 9.69% 16.5%
Total Long-Term Liabilities $7.346M $6.950M $7.415M
YoY Change 10.17% 9.69% 16.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.51M $20.35M $16.80M
Total Long-Term Liabilities $7.346M $6.950M $7.415M
Total Liabilities $26.85M $27.30M $24.21M
YoY Change -8.74% -8.29% -16.0%
SHAREHOLDERS EQUITY
Retained Earnings -$375.6M -$345.7M -$323.6M
YoY Change 33.44% 30.88% 30.85%
Common Stock $664.8M $662.8M $477.7M
YoY Change 40.33% 85.58% 42.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $291.8M $319.8M $156.7M
YoY Change
Total Liabilities & Shareholders Equity $318.7M $347.1M $181.0M
YoY Change 42.04% 176.48% 51.0%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$29.90M -$22.06M -$23.14M
YoY Change 72.53% 31.23% 53.96%
Depreciation, Depletion And Amortization $579.0K $760.0K $730.0K
YoY Change 23.72% 5.56% -5.19%
Cash From Operating Activities -$31.88M -$14.96M -$17.45M
YoY Change 85.35% 12.31% 59.36%
INVESTING ACTIVITIES
Capital Expenditures $195.0K -$2.320M -$980.0K
YoY Change 20.37% 2009.09% 1300.0%
Acquisitions
YoY Change
Other Investing Activities -$81.13M -$11.50M $6.540M
YoY Change 74.77% 159.59% 7.92%
Cash From Investing Activities -$81.33M -$13.82M $5.560M
YoY Change 74.6% 204.41% -7.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K 183.6M 630.0K
YoY Change -99.39% 837.92% -93.42%
NET CHANGE
Cash From Operating Activities -31.88M -14.96M -17.45M
Cash From Investing Activities -81.33M -13.82M 5.560M
Cash From Financing Activities 700.0K 183.6M 630.0K
Net Change In Cash -112.5M 154.8M -11.26M
YoY Change -321.78% 8950.88% -343.72%
FREE CASH FLOW
Cash From Operating Activities -$31.88M -$14.96M -$17.45M
Capital Expenditures $195.0K -$2.320M -$980.0K
Free Cash Flow -$32.08M -$12.64M -$16.47M
YoY Change 84.74% -4.31% 51.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23833000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
424000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
305189000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7205000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
8965000 USD
CY2012Q4 us-gaap Assets
Assets
125541000 USD
CY2013Q4 us-gaap Assets
Assets
347095000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
745000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10960000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
388000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
5592000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17685000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20350000 USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
5746000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6336000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
29767000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
64000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
357094000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2745000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264129000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
95774000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125541000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
319795000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
2342000 USD
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
85553000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-43399000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-81442000 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64359513 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89246832 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89246832 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64359513 shares
CY2012 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
146000 USD
CY2011 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
110000 USD
CY2012 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
281000 USD
CY2011 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
36000 USD
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
10775000 USD
CY2011 us-gaap Royalty Revenue
RoyaltyRevenue
9119000 USD
CY2012 us-gaap Revenues
Revenues
11202000 USD
CY2011 us-gaap Revenues
Revenues
9265000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32439000 USD
CY2012 us-gaap Royalty Expense
RoyaltyExpense
10775000 USD
CY2011 us-gaap Royalty Expense
RoyaltyExpense
9119000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10016000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9193000 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1090000 USD
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
69279000 USD
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
52664000 USD
CY2013 us-gaap Royalty Expense
RoyaltyExpense
2334000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-58077000 USD
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
530000 USD
CY2011 us-gaap Interest And Other Income
InterestAndOtherIncome
396000 USD
CY2012 us-gaap Interest Expense
InterestExpense
1576000 USD
CY2011 us-gaap Interest Expense
InterestExpense
1796000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59123000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81550000 USD
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57713000 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39501000 shares
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2047000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2248000 USD
CY2012 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000 USD
CY2011 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9000 USD
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
91000 USD
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-90000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59030000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44898000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81627000 USD
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
660000 USD
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-17000 USD
CY2012 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
6000 USD
CY2011 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-5000 USD
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
74000 USD
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
58000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
2298000 USD
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
226000 USD
CY2011 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
307000 USD
CY2012 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-126000 USD
CY2011 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-154000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-241000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
95000 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-34000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3762000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2076000 USD
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
594000 USD
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-138000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-49782000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35658000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-67669000 USD
CY2012 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
52360000 USD
CY2011 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
51003000 USD
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69255000 USD
CY2011 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52717000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
303000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
509000 USD
CY2012 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
218000 USD
CY2011 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
68000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16980000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2155000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-77422000 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83784000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36023000 USD
CY2013 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
5403000 USD
CY2013 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
-11029000 USD
CY2012 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
-3971000 USD
CY2011 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000 USD
CY2011 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12503000 USD
CY2011 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
86000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28434000 USD
CY2012 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
55000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
79758000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
289599000 USD
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
2000 USD
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-9000 USD
CY2012 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
12998000 USD
CY2011 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-9388000 USD
CY2013 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
144505000 USD
CY2012 us-gaap Interest Paid
InterestPaid
1384000 USD
CY2011 us-gaap Interest Paid
InterestPaid
1560000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
75255000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
68722000 USD
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
173000 USD
CY2011 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2155000 USD
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33695000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2342000 USD
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
163000 USD
CY2012 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
40138000 USD
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
43483000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2298000 USD
CY2013 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
17134000 USD
CY2013 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>(1) NATURE OF BUSINESS AND OVERVIEW</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Celldex Therapeutics,&#160;Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (also referred to as CDX-110) and glembatumumab vedotin (also referred to as CDX-011). Rindopepimut is a targeted immunotherapeutic in a pivotal Phase&#160;3 study for the treatment of front-line glioblastoma and a Phase&#160;2 study for the treatment of recurrent glioblastoma. Glembatumumab vedotin is an antibody-drug conjugate in a randomized study in patients with triple negative breast cancer that over-express gpNMB designed to obtain accelerated approval. The Company has a number of earlier stage candidates in clinical development, including varlilumab (also referred to as CDX-1127), a fully human therapeutic monoclonal antibody in a Phase&#160;1 study for cancer indications, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December&#160;31, 2013, the Company had cash, cash equivalents and marketable securities of $303.0&#160;million. The Company incurred a loss of $81.6&#160;million for the year ended December&#160;31, 2013. Net cash used in operations for the year ended December&#160;31, 2013 was $67.7&#160;million. The Company believes that the cash, cash equivalents and marketable securities at December&#160;31, 2013 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company's economic potential from products under development.</font></p> </div>
CY2013 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013Q2 dei Entity Public Float
EntityPublicFloat
1300000000 USD
CY2013 dei Entity Registrant Name
EntityRegistrantName
Celldex Therapeutics, Inc.
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0000744218
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89251747 shares
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1366000 USD
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
21000 USD
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-276000 USD
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
112118000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4219000 USD
CY2013 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
472000 USD
CY2013 us-gaap Interest Paid
InterestPaid
1209000 USD
CY2013Q4 us-gaap Investments And Cash
InvestmentsAndCash
303000000 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><i>Use of Estimates</i></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><i>Concentration of Credit Risk and of Significant Customers and Suppliers</i></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue from Glaxo represented 57%, 96% and 98% for the years ended December&#160;31, 2013, 2012 and 2011 and of total Company revenue, respectively.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company relies on contract manufacturing organizations (CMO) to manufacture drug substance and drug product for its late-stage clinical studies of rindopepimut and glembatumumab vedotin as well as for future commercial supplies. The Company also relies on CMOs for supply of raw materials as well as filling, packaging, storage and shipping of drug product. These clinical studies would be adversely affected by a significant interruption in the supply of rindopepimut and glembatumumab vedotin.</font></p> </div>
CY2013Q4 cldx Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
104000 USD
CY2012Q4 cldx Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
8000 USD
CY2013Q4 cldx Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
22000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59065000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
133581000 USD
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2600000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2600000 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5355810 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4465034 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5776544 shares
CY2013Q4 cldx Fair Value Liabilities Amount Transfers Between Measurement Levels
FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels
0 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
58909000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
133499000 USD
CY2012Q4 cldx Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
164000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2668000 USD
CY2013 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-77000 USD
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1013000 USD
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-77000 USD
CY2013Q4 cldx Fair Value Assets Amount Transfers Between Measurement Levels
FairValueAssetsAmountTransfersBetweenMeasurementLevels
0 USD
CY2013Q4 cldx Available For Sale Securities Considered To Be Other Than Temporarily Impaired
AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired
0 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19530000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12325000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21965000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11992000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9973000 USD
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1932000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
8965000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3763000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4776000 USD
CY2012Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
27596000 USD
CY2013Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
27596000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
22820000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
900000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
900000 USD
CY2012Q4 cldx Accrued Royalty And License Fees Current
AccruedRoyaltyAndLicenseFeesCurrent
1776000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
925000 USD
CY2012Q4 cldx Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
7569000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
317000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
373000 USD
CY2013Q4 cldx Accrued Royalty And License Fees Current
AccruedRoyaltyAndLicenseFeesCurrent
250000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3515000 USD
CY2013Q4 cldx Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
11840000 USD
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1018000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17179000 USD
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
419000 USD
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
434000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2012Q4 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
1118000 USD
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5403000 USD
CY2012Q4 us-gaap Loans Payable
LoansPayable
472000 USD
CY2012Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
39000 USD
CY2012Q4 us-gaap Other Liabilities
OtherLiabilities
6724000 USD
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
4661000 USD
CY2013Q4 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
1630000 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
1168000 USD
CY2013Q4 us-gaap Other Liabilities
OtherLiabilities
7878000 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
928000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6950000 USD
CY2011Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
600000 USD
CY2012Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
800000 USD
CY2013Q1 cldx Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
800000 USD
CY2012Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
700000 USD
CY2011Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
500000 USD
CY2013Q1 cldx Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
800000 USD
CY2013 cldx Period For Which Base Of Operations Must Be Maintained
PeriodForWhichBaseOfOperationsMustBeMaintained
P5Y
CY2012 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
100000 USD
CY2013 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
200000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
79558000 USD
CY2010Q2 cldx Shelf Registration Statement Amount
ShelfRegistrationStatementAmount
150000000 USD
CY2012Q4 cldx Shelf Registration Statement Amount
ShelfRegistrationStatementAmount
200000000 USD
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3261000 USD
CY2013 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
21613483 shares
CY2013Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
489000 USD
CY2011 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11500000 shares
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
25582000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
61370000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1717000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2243000 USD
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7813483 shares
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3926000 USD
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1638000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
623000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
27300000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
89000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
662717000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345679000 USD
CY2012 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
1426000 USD
CY2011 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
411000 USD
CY2012 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
1426000 USD
CY2011 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
411000 USD
CY2013 cldx Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
126000 USD
CY2012 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
-22205000 USD
CY2011 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
-19008000 USD
CY2013 cldx Income Tax Expense Benefit Before Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance
-35756000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-22205000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-19008000 USD
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-35756000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-20102000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15213000 USD
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-27727000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
1736000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
167000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4237000 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3131000 USD
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4920000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
708000 USD
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
661000 USD
CY2013 cldx Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
126000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22205000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
19008000 USD
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
35756000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67728000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
20692000 USD
CY2012 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-19394000 USD
CY2011 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-16204000 USD
CY2013 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-30962000 USD
CY2012 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-4237000 USD
CY2011 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-3131000 USD
CY2013 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-4920000 USD
CY2011 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
-84000 USD
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
26000 USD
CY2013 cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
1617000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
43226000 USD
CY2013 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
160000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67401000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3264000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14805000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
2156000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
241000 USD
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
819000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
137307000 USD
CY2012Q4 cldx Deferred Tax Liabilities Other Acquired Intangible Assets
DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets
4481000 USD
CY2013Q4 cldx Deferred Tax Liabilities Other Acquired Intangible Assets
DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets
4115000 USD
CY2012Q4 cldx Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
4661000 USD
CY2013Q4 cldx Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
4661000 USD
CY2012Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9142000 USD
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8776000 USD
CY2012Q4 cldx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
128165000 USD
CY2013Q4 cldx Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
163921000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
132826000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168582000 USD
CY2013Q4 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
3 item
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2666000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2863000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2914000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1765000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
501000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10876000 USD
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2500000 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2500000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000 USD
CY2013 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50 pure
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 USD
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2012Q1 us-gaap Revenues
Revenues
2433000 USD
CY2012Q2 us-gaap Revenues
Revenues
2009000 USD
CY2012Q3 us-gaap Revenues
Revenues
3113000 USD
CY2012Q4 us-gaap Revenues
Revenues
3647000 USD
CY2013Q1 us-gaap Revenues
Revenues
2414000 USD
CY2013Q2 us-gaap Revenues
Revenues
97000 USD
CY2013Q3 us-gaap Revenues
Revenues
980000 USD
CY2013Q4 us-gaap Revenues
Revenues
620000 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13516000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13773000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15027000 USD
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16807000 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17332000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19016000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23140000 USD
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22062000 USD
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2298000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2342000 USD
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4548000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
172697000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
278563000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4548000 USD
CY2013 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000 USD
CY2013 us-gaap Interest Expense
InterestExpense
927000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169402000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11899000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21287000 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79777000 shares
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
4548000 USD
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
97000 USD
CY2013 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
445000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
706000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7236000 USD
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1317000 USD
CY2013 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38894000 USD
CY2013 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
21000 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
295697000 USD
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-3000 USD
CY2013 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0 USD
CY2012 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0 USD
CY2011 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0 USD
CY2013Q4 cldx Expected Dividend Payable In Foreseeable Future
ExpectedDividendPayableInForeseeableFuture
0 USD
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
6000000 USD

Files In Submission

Name View Source Status
0001047469-14-001653-index-headers.html Edgar Link pending
0001047469-14-001653-index.html Edgar Link pending
0001047469-14-001653.txt Edgar Link pending
0001047469-14-001653-xbrl.zip Edgar Link pending
a2218459z10-k.htm Edgar Link pending
a2218459zex-21_0.htm Edgar Link pending
a2218459zex-23_1.htm Edgar Link pending
a2218459zex-31_1.htm Edgar Link pending
a2218459zex-31_2.htm Edgar Link pending
a2218459zex-32.htm Edgar Link pending
cldx-20131231.xml Edgar Link completed
cldx-20131231.xsd Edgar Link pending
cldx-20131231_cal.xml Edgar Link unprocessable
cldx-20131231_def.xml Edgar Link unprocessable
cldx-20131231_lab.xml Edgar Link unprocessable
cldx-20131231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g621270.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending